The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants
For study participants of Japanese origin: study participant who is born in Japan and of Japanese descent as evidenced in appearance and verbal confirmation of familial heritage with all 4 grandparents and both parents born in Japan and has not had a significant change in lifestyle or diet since leaving Japan
Study participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent
Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
Body weight within 40 kilograms (kg) to 110 kg and body mass index (BMI) within the range of 18 kilograms per meter square (kg/m2) to 30 kg/m2 (inclusive)
Study participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
Study participant has a recent history (within 6 months of Screening) or currently active clinically significant bacterial, fungal, endoparasite, or viral infection.
Study participant has a significant allergy to humanized monoclonal antibody (mAbs)
Sequential
UCB5285
DrugParticipants will receive UCB5285 as prespecified in each cohort.
Placebo
Other interventionParticipants will receive matching placebo as prespecified in each cohort.
8
Treatment groupsSee each treatment group below.
Incidence of Treatment-Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency.
Incidence of Treatment-Emergent Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
Maximum Observed Serum Concentration (Cmax) of UCB5285
Maximum observed serum concentration (Cmax) of UCB5285
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC) of UCB5285
Area under the serum concentration-time curve from time zero to infinity (AUC) of UCB5285
Area Under the Serum Concentration-Time Curve from Time Zero to the Time of Last Detectable Concentration (AUC0-t) of UCB5285
Area under the serum concentration-time curve from time zero to the time of last detectable concentration (AUC0-t) of UCB5285
Click on the lead sponsor to view all of their trials.
